Biology Reference
In-Depth Information
26. Ferrari M (2005) Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer
5(3):161-171
27. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R (2007) Nanocarriers as an
emerging platform for cancer therapy. Nat Nanotechnol 2(12):751-760
28. Mizrahy S, Peer D (2012) Polysaccharides as building blocks for nanotherapeutics. Chem Soc
Rev 41(7):2623-2640
29. Schroeder A, Heller DA, Winslow MM, Dahlman JE, Pratt GW, Langer R et al (2012) Treating
metastatic cancer with nanotechnology. Nat Rev Cancer 12(1):39-50
30. Wang J, Byrne JD, Napier ME, DeSimone JM (2011) More effective nanomedicines through
particle design. Small 7(14):1919-1931
31. Moghimi SM, Peer D, Langer R (2011) Reshaping the future of nanopharmaceuticals: ad iudi-
cium. ACS Nano 5(11):8454-8458
32. Bitko V, Musiyenko A, Shulyayeva O, Barik S (2005) Inhibition of respiratory viruses by
nasally administered siRNA. Nat Med 11(1):50-55
33. Palliser D, Chowdhury D, Wang QY, Lee SJ, Bronson RT, Knipe DM et al (2006) An siRNA-
based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature
439(7072):89-94
34. Kim B, Tang Q, Biswas PS, Xu J, Schiffelers RM, Xie FY et al (2004) Inhibition of ocular
angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeu-
tic strategy for herpetic stromal keratitis. Am J Pathol 165(6):2177-2185
35. Juliano R, Bauman J, Kang H, Ming X (2009) Biological barriers to therapy with antisense and
siRNA oligonucleotides. Mol Pharm 6(3):686-695
36. Zender L, Kubicka S (2007) Suppression of apoptosis in the liver by systemic and local deliv-
ery of small-interfering RNAs. Methods Mol Biol 361:217-226
37. De Souza AT, Dai X, Spencer AG, Reppen T, Menzie A, Roesch PL et al (2006) Transcriptional
and phenotypic comparisons of Ppara knockout and siRNA knockdown mice. Nucleic Acids
Res 34(16):4486-4494
38. Saito Y, Kon S, Fujiwara Y, Nakayama Y, Kurotaki D, Fukuda N et al (2007) Osteopontin
small interfering RNA protects mice from fulminant hepatitis. Hum Gene Ther 18(12):
1205-1214
39. Lewis DL, Wolff JA (2007) Systemic siRNA delivery via hydrodynamic intravascular injec-
tion. Adv Drug Deliv Rev 59(2-3):115-123
40. Molitoris BA, Dagher PC, Sandoval RM, Campos SB, Ashush H, Fridman E et al (2009)
siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. J Am
Soc Nephrol 20(8):1754-1764
41. Peer D, Lieberman J (2011) Special delivery: targeted therapy with small RNAs. Gene Ther
18(12):1127-1133
42. Mizrahy S, Raz SR, Hasgaard M, Liu H, Soffer-Tsur N, Cohen K et al (2011) Hyaluronan-
coated nanoparticles: the influence of the molecular weight on CD44-hyaluronan interactions
and on the immune response. J Control Release 156(2):231-238
43. Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer
chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent
smancs. Cancer Res 46(12 Pt 1):6387-6392
44. Maeda H (2001) The enhanced permeability and retention (EPR) effect in tumor vasculature:
the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 41:
189-207
45. Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN et al (2006) RNAi-
mediated gene silencing in non-human primates. Nature 441(7089):111-114
46. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W et al (2005) Potent
and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol
23(8):1002-1007
47. Geisbert TW, Hensley LE, Kagan E, Yu EZ, Geisbert JB, Daddario-DiCaprio K et al (2006)
Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by
RNA interference. J Infect Dis 193(12):1650-1657
Search WWH ::
Custom Search